• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Philips recruits MI partner

Article

Biotechnology firm CellPoint of Englewood, CO, is collaborating with Philips Medical Systems to optimize an advanced molecular imaging agent for use on the Dutch company's Skylight gantryless gamma camera. The joint goal is to develop a cost-effective,

Biotechnology firm CellPoint of Englewood, CO, is collaborating with Philips Medical Systems to optimize an advanced molecular imaging agent for use on the Dutch company's Skylight gantryless gamma camera. The joint goal is to develop a cost-effective, readily accessible technology for diagnosing cancer and prescreening patients for therapy. The focus of the agreement is CellPoint's ethylenedicysteine (EC) drug conjugate, which chemically links tissue-specific ligands (such as hormones, proteins, peptides, and glucose analogues) or pharmaceutical compounds to radioisotopes. The combined agents are being designed for cancer diagnosis and treatment. The two companies will collaborate on CellPoint's first molecular imaging agent, Tc-99m-EC-deoxyglucose, which allows deoxyglucose to be labeled with technetium-99m. Such unions with Tc-99m have been difficult to forge because the radioisotope is resistant to currently available coupling compounds. EC promises to overcome that difficulty. Philips and CellPoint will share clinical trial costs to develop this technology, according to executives at the companies. Phase I clinical studies began April 2003 at the University of Texas M. D. Anderson Cancer Center in Houston. Philips plans to review trial data and determine whether adjustments in acquisition protocols or postprocessing are needed to improve image quality.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.